Liquid Biopsy Predicts Response to Breast Cancer Immunotherapy

Why It Matters

Predictive liquid biopsies enable clinicians to tailor immunotherapy, improving response rates and avoiding unnecessary toxicity, and could accelerate precision oncology across solid tumors.

Key Takeaways

• RNA profiling of blood predicts pembrolizumab response in HER2‑negative breast cancer
• Study analyzed 546 samples from 160 patients across the I‑SPY2 trial
• T‑cell activation signatures serve as real‑time biomarkers for immunotherapy efficacy
• Liquid biopsy offers a less invasive, cost‑effective alternative to tissue sampling

Pulse Analysis

Immunotherapy, particularly checkpoint inhibitors such as pembrolizumab, has reshaped treatment algorithms for high‑risk early‑stage breast cancer, yet response rates remain modest. Oncologists lack reliable tools to identify patients who will benefit before committing to costly and potentially toxic regimens. Traditional tissue biopsies provide a static snapshot and often require invasive procedures, limiting their utility for dynamic monitoring. Consequently, the field has turned to liquid biopsies—blood‑based assays that can be repeated over time—to capture the evolving tumor‑immune interplay.

The Vanderbilt‑Ingram Cancer Center leveraged this concept by performing RNA sequencing on 546 peripheral‑blood draws from 160 HER2‑negative stage 2‑3 breast cancer patients enrolled in the I‑SPY2 neoadjuvant trial. By profiling the transcriptome of circulating immune cells, the researchers identified a signature of clonal T‑cell expansion that correlated strongly with pathological complete response to pembrolizumab‑combined chemotherapy. This approach transformed a simple blood draw into a predictive readout, outperforming conventional imaging and offering a quantitative metric that can be tracked throughout treatment cycles.

If validated in larger cohorts, this liquid‑biopsy platform could become a decision‑support tool that guides immunotherapy selection, escalates or de‑escalates therapy in real time, and reduces exposure to ineffective drugs. Its cost‑effectiveness and minimal invasiveness make it attractive for community oncology practices, potentially expanding precision oncology beyond academic centers. Moreover, the underlying methodology—monitoring immune‑related transcriptional changes in blood—may translate to other solid tumors where checkpoint blockade is emerging, accelerating the broader adoption of adaptive treatment strategies.